Wound Management News

Increased use of postoperative courses of oral antibiotics prescribed by dermatologists after surgical procedures may put patients at risk for adverse events, according to a study.

Researchers explored the skin-related conditions associated with electronic cigarette use in a literature review and concluded that e-cigarettes are not safe alternatives to traditional tobacco cigarettes in developing dermatological issues.

Argentum Medical announced that it has been awarded a 3-year, $8.4 million contract with the Biomedical Advanced Research and Developmental Authority, or BARDA, to repurpose its commercial Silverlon technology for skin injuries occurring during radiological and nuclear emergencies.

The FDA granted premarket approval to Recell, a spray-on-skin agent, to treat burns in patients aged older than 18 years, its manufacturer announced.

The FDA has approved an oral formulation of TPOXX for the treatment of smallpox, citing concerns that the infectious disease, long considered eradicated since 1980, could potentially be used as a bioweapon, according to a press release.

Fireworks are a ubiquitous presence among Fourth of July celebrations; however, these bright and colorful displays pose a danger to children who may want to handle these dangerous products.

ATLANTA — To help improve the care of troops injured in combat, the United States military has been exploring the complex microbiology of combat wounds.

Methicillin-susceptible Staphylococcus aureus has begun to incur similar hospitalization costs and may ultimately exceed those of MRSA, researchers reported in Clinical Infectious Diseases.

Motif Bio announced additional safety data from its REVIVE-2 trial of the investigational antibiotic iclaprim, showing that the treatment was well-tolerated in patients with acute bacterial skin and skin structure infections, or ABSSSIs. Other findings, presented at the European Congress of Clinical Microbiology and Infectious Diseases, showed that the drug could reduce the cost burden of acute kidney injury normally associated with vancomycin, which is currently the standard of care.

Omadacycline is effective in treating acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, according to topline results presented at the European Congress of Clinical Microbiology and Infectious Diseases.